Index -
P/E 30.29
EPS (ttm) 11.42
Insider Own 17.93%
Shs Outstand 31.01M
Perf Week -1.31%
Market Cap 10.75B
Forward P/E 27.72
EPS next Y 12.48
Insider Trans -0.15%
Shs Float 25.51M
Perf Month -4.42%
Income 365.57M
PEG 2.00
EPS next Q 2.94
Inst Own 82.82%
Short Float 4.46%
Perf Quarter -3.02%
Sales 2.07B
P/S 5.19
EPS this Y 34.41%
Inst Trans 0.90%
Short Ratio 3.04
Perf Half Y -12.18%
Book/sh 28.42
P/B 12.17
EPS next Y 4.54%
ROA 20.48%
Short Interest 1.14M
Perf Year 16.43%
Cash/sh 21.13
P/C 16.37
EPS next 5Y 15.15%
ROE 54.06%
52W Range 277.72 - 459.77
Perf YTD 12.85%
Dividend Est. -
P/FCF 20.07
EPS past 5Y 35.06%
ROI 36.21%
52W High -24.76%
Beta 1.36
Dividend TTM -
Quick Ratio 0.99
Sales past 5Y 22.02%
Gross Margin 28.30%
52W Low 24.56%
ATR (14) 11.19
Dividend Ex-Date -
Current Ratio 0.99
EPS Y/Y TTM 33.66%
Oper. Margin 19.74%
RSI (14) 53.14
Volatility 3.09% 3.53%
Employees 5900
Debt/Eq 0.17
Sales Y/Y TTM 16.24%
Profit Margin 17.65%
Recom 2.27
Target Price 354.75
Option/Short Yes / Yes
LT Debt/Eq 0.15
EPS Q/Q 35.38%
Payout 0.00%
Rel Volume 0.73
Prev Close 347.43
Sales Surprise -1.42%
EPS Surprise 8.64%
Sales Q/Q 8.29%
Earnings Oct 21 AMC
Avg Volume 374.46K
Price 345.93
SMA20 2.61%
SMA50 1.96%
SMA200 -8.12%
Trades
Volume 272,235
Change -0.43%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-23-24 Downgrade
Robert W. Baird
Outperform → Neutral
$413 → $349
Oct-14-24 Initiated
Redburn Atlantic
Buy
Sep-27-24 Downgrade
UBS
Buy → Neutral
$420 → $350
Sep-25-24 Downgrade
Jefferies
Buy → Hold
$415 → $345
Aug-01-24 Initiated
Truist
Hold
$415
May-29-24 Initiated
TD Cowen
Buy
$452
May-28-24 Initiated
Mizuho
Buy
$435
Apr-23-24 Upgrade
Jefferies
Hold → Buy
$340 → $450
Mar-18-24 Initiated
Deutsche Bank
Hold
$395
Feb-15-24 Upgrade
UBS
Neutral → Buy
$282 → $452
Oct-24-23 Upgrade
Robert W. Baird
Neutral → Outperform
$270 → $289
May-08-23 Upgrade
Guggenheim
Neutral → Buy
$252
Oct-27-22 Upgrade
UBS
Sell → Neutral
$142 → $238
Sep-07-22 Initiated
UBS
Sell
$142
May-24-22 Initiated
Guggenheim
Neutral
Aug-05-21 Resumed
Credit Suisse
Outperform
$205
Oct-02-20 Upgrade
Truist
Hold → Buy
$124 → $135
Jun-08-20 Upgrade
Robert W. Baird
Underperform → Neutral
$83
May-13-20 Downgrade
Wolfe Research
Outperform → Peer Perform
Apr-30-20 Upgrade
SunTrust
Sell → Hold
$85
Show Previous Ratings
Nov-21-24 06:52PM
Nov-15-24 06:47PM
(Morningstar Research) -7.23%
Nov-06-24 06:36PM
(Morningstar Research) +9.15%
Nov-04-24 10:12AM
Nov-01-24 07:33PM
09:00PM
Loading…
Oct-29-24 09:00PM
Oct-23-24 03:56AM
(Thomson Reuters StreetEvents)
Oct-22-24 05:42PM
(Morningstar Research) -7.47%
04:04PM
(Investor's Business Daily)
10:09AM
Oct-21-24 04:25PM
(Associated Press Finance)
04:15PM
Oct-16-24 11:23AM
10:44AM
Oct-10-24 01:56PM
07:42AM
Loading…
07:42AM
Oct-08-24 09:00PM
Sep-30-24 09:00PM
Sep-24-24 05:26PM
04:05PM
Aug-30-24 09:00PM
Aug-29-24 12:40PM
Aug-26-24 04:02PM
Aug-19-24 09:00PM
Aug-16-24 06:45AM
Aug-15-24 02:48PM
Aug-12-24 10:11AM
Aug-05-24 04:08PM
Aug-02-24 07:46PM
Jul-25-24 10:04AM
01:01AM
Loading…
Jul-24-24 01:01AM
12:55AM
(Thomson Reuters StreetEvents)
Jul-23-24 06:24PM
(Morningstar Research) -18.27%
Jul-22-24 04:21PM
(Associated Press Finance)
04:15PM
Jul-19-24 11:50AM
Jul-18-24 09:15AM
Jul-12-24 06:15PM
Jul-11-24 12:00PM
Jun-28-24 09:15AM
Jun-27-24 06:37PM
Jun-26-24 06:15PM
04:05PM
Jun-18-24 06:13AM
(Pharmaceutical Technology)
Jun-17-24 06:15PM
Jun-12-24 04:00AM
Jun-10-24 06:15PM
May-29-24 12:45PM
May-17-24 04:17PM
May-14-24 04:25PM
May-13-24 12:45PM
May-10-24 09:40AM
08:58AM
May-09-24 09:00AM
May-08-24 04:54PM
May-03-24 04:13PM
09:30AM
May-01-24 04:59PM
Apr-25-24 06:37PM
12:45PM
Apr-24-24 10:37AM
09:58AM
03:08AM
Apr-23-24 10:35PM
(Thomson Reuters StreetEvents) +8.21%
Apr-22-24 05:31PM
05:25PM
04:47PM
04:24PM
(Associated Press Finance)
04:15PM
Apr-15-24 10:00AM
Apr-10-24 09:43AM
Apr-08-24 04:45PM
Apr-05-24 12:10PM
04:33AM
Apr-01-24 07:16AM
(Investor's Business Daily)
Mar-28-24 04:05PM
Mar-23-24 09:00AM
(The Wall Street Journal)
Mar-22-24 09:20AM
Mar-19-24 10:48AM
Mar-18-24 08:27AM
Mar-08-24 05:00PM
Mar-04-24 12:45PM
12:00PM
Feb-29-24 03:14AM
Feb-21-24 09:13AM
Feb-17-24 09:38AM
Feb-15-24 10:38AM
08:41AM
Feb-14-24 05:06PM
(Morningstar Research) +7.06%
Feb-13-24 10:24PM
(Thomson Reuters StreetEvents) +12.30%
06:53PM
Feb-12-24 04:43PM
(Associated Press Finance)
04:34PM
04:15PM
Jan-18-24 04:05AM
Jan-12-24 09:37AM
Jan-03-24 04:05PM
Dec-26-23 06:56PM
Dec-15-23 09:15AM
Dec-13-23 12:04PM
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GEIGER JESSE J President Dec 06 '24 Option Exercise 32.05 15,000 480,750 36,503 Dec 10 04:24 PM BURWIG SUSAN E Exec. VP, Operations Nov 19 '24 Option Exercise 32.05 7,500 240,375 65,000 Nov 21 04:40 PM Kraft Robert O. Director Aug 22 '24 Option Exercise 42.62 4,353 185,525 4,873 Aug 26 04:37 PM Kraft Robert O. Director Aug 23 '24 Option Exercise 42.62 3,774 160,848 4,294 Aug 26 04:37 PM Kraft Robert O. Director Aug 22 '24 Sale 390.73 4,353 1,700,848 520 Aug 26 04:37 PM Kraft Robert O. Director Aug 23 '24 Sale 390.73 3,774 1,474,615 520 Aug 26 04:37 PM Kraft Robert O. Director Aug 22 '24 Proposed Sale 390.73 4,353 1,700,858 Aug 22 04:20 PM Keating Ashley M. Former Director Aug 16 '24 Proposed Sale 387.00 769 297,603 Aug 16 04:58 PM Keating Ashley M. Former Director Aug 15 '24 Proposed Sale 388.00 958 371,704 Aug 15 06:27 PM Keating Ashley M. Former Director Aug 09 '24 Proposed Sale 388.29 1,403 544,767 Aug 09 03:50 PM BURWIG SUSAN E Exec. VP, Operations Aug 05 '24 Option Exercise 90.65 50,000 4,532,500 57,500 Aug 07 04:22 PM Keating Ashley M. Former Director Aug 06 '24 Proposed Sale 382.50 2,000 765,000 Aug 06 05:27 PM Keating Ashley M. Former Director Jul 30 '24 Proposed Sale 389.69 1,300 506,600 Jul 30 01:23 PM BURWIG SUSAN E Exec. VP, Operations Jun 05 '24 Sale 401.20 7,681 3,081,617 7,500 Jun 07 04:17 PM Troendle August J. CEO May 28 '24 Sale 395.49 5,695 2,252,316 654,656 May 29 04:24 PM Troendle August J. CEO May 24 '24 Sale 395.22 3,987 1,575,742 660,351 May 29 04:24 PM Troendle August J. CEO May 22 '24 Sale 400.00 55 22,000 664,338 May 24 04:10 PM Troendle August J. CEO May 20 '24 Sale 400.19 4,020 1,608,764 664,393 May 22 04:20 PM Troendle August J. CEO May 15 '24 Sale 405.13 32,282 13,078,407 675,473 May 17 04:12 PM Troendle August J. CEO May 16 '24 Sale 403.09 7,060 2,845,815 668,413 May 17 04:12 PM Troendle August J. CEO May 10 '24 Sale 402.89 4,956 1,996,723 707,755 May 14 04:11 PM Troendle August J. CEO May 08 '24 Sale 400.58 4,782 1,915,574 716,197 May 10 04:24 PM Troendle August J. CEO May 09 '24 Sale 400.17 3,486 1,394,993 712,711 May 10 04:24 PM Troendle August J. CEO May 07 '24 Sale 404.48 28,032 11,338,383 720,979 May 08 04:08 PM Troendle August J. CEO May 06 '24 Sale 401.73 24,372 9,790,964 749,011 May 08 04:08 PM Troendle August J. CEO May 01 '24 Sale 401.56 12,934 5,193,777 776,779 May 03 04:07 PM Troendle August J. CEO May 02 '24 Sale 400.44 3,396 1,359,894 773,383 May 03 04:07 PM Troendle August J. CEO Apr 29 '24 Sale 400.69 15,102 6,051,220 791,541 May 01 04:22 PM Troendle August J. CEO Apr 30 '24 Sale 400.31 1,828 731,767 789,713 May 01 04:22 PM BURWIG SUSAN E Exec. VP, Operations Mar 15 '24 Sale 403.00 102 41,106 15,181 Mar 19 05:11 PM Keating Ashley M. Director Mar 14 '24 Option Exercise 84.36 500 42,180 500 Mar 18 05:10 PM Keating Ashley M. Director Mar 14 '24 Sale 409.87 250 102,468 250 Mar 18 05:10 PM Troendle August J. CEO Mar 06 '24 Sale 412.98 100,000 41,298,000 4,833,019 Mar 08 05:08 PM Troendle August J. CEO Mar 07 '24 Sale 410.74 75,000 30,805,500 4,758,019 Mar 08 05:08 PM Troendle August J. CEO Mar 08 '24 Sale 408.71 25,000 10,217,750 4,733,019 Mar 08 05:08 PM Medpace Investors, LLC 10% Owner Mar 06 '24 Sale 412.98 100,000 41,298,000 4,833,019 Mar 08 05:02 PM Medpace Investors, LLC 10% Owner Mar 07 '24 Sale 410.74 75,000 30,805,500 4,758,019 Mar 08 05:02 PM Medpace Investors, LLC 10% Owner Mar 08 '24 Sale 408.71 25,000 10,217,750 4,733,019 Mar 08 05:02 PM Keating Ashley M. Director Mar 07 '24 Option Exercise 54.99 472 25,955 472 Mar 08 04:12 PM Keating Ashley M. Director Mar 07 '24 Sale 415.00 472 195,880 0 Mar 08 04:12 PM GEIGER JESSE J President Mar 04 '24 Option Exercise 90.65 22,321 2,023,399 26,145 Mar 06 04:42 PM GEIGER JESSE J President Mar 05 '24 Option Exercise 90.65 17,679 1,602,601 21,503 Mar 06 04:42 PM GEIGER JESSE J President Mar 04 '24 Sale 403.03 22,321 8,996,033 3,824 Mar 06 04:42 PM Troendle August J. CEO Mar 04 '24 Sale 403.12 50,000 20,156,000 4,983,019 Mar 06 04:36 PM Troendle August J. CEO Mar 05 '24 Sale 402.70 50,000 20,135,000 4,933,019 Mar 06 04:36 PM Medpace Investors, LLC 10% Owner Mar 04 '24 Sale 403.12 50,000 20,156,000 4,983,019 Mar 06 04:28 PM Medpace Investors, LLC 10% Owner Mar 05 '24 Sale 402.70 50,000 20,135,000 4,933,019 Mar 06 04:28 PM Medpace Investors, LLC 10% Owner Mar 01 '24 Sale 401.88 80,000 32,150,400 5,033,019 Mar 04 04:38 PM Medpace Investors, LLC 10% Owner Feb 29 '24 Sale 393.71 20,000 7,874,200 5,113,019 Mar 04 04:38 PM Troendle August J. CEO Mar 01 '24 Sale 401.88 80,000 32,150,400 5,033,019 Mar 04 04:15 PM Troendle August J. CEO Feb 29 '24 Sale 393.71 20,000 7,874,200 5,113,019 Mar 04 04:15 PM EWALD STEPHEN P General Counsel & Corp. Secy. Feb 29 '24 Sale 393.50 1,163 457,646 13,691 Mar 01 04:32 PM EWALD STEPHEN P General Counsel & Corp. Secy. Mar 01 '24 Sale 400.79 350 140,276 13,341 Mar 01 04:32 PM GEIGER JESSE J President Feb 29 '24 Sale 393.50 2,558 1,006,586 3,824 Mar 01 04:25 PM Keating Ashley M. Director Feb 28 '24 Option Exercise 54.99 500 27,495 500 Mar 01 04:17 PM Keating Ashley M. Director Feb 28 '24 Sale 405.00 500 202,500 0 Mar 01 04:17 PM Troendle August J. CEO Feb 28 '24 Sale 404.13 50,000 20,206,500 5,133,019 Feb 29 04:16 PM Troendle August J. CEO Feb 27 '24 Sale 401.88 50,000 20,094,000 5,183,019 Feb 29 04:16 PM Medpace Investors, LLC 10% Owner Feb 28 '24 Sale 404.13 50,000 20,206,500 5,133,019 Feb 29 04:11 PM Medpace Investors, LLC 10% Owner Feb 27 '24 Sale 401.88 50,000 20,094,000 5,183,019 Feb 29 04:11 PM Troendle August J. CEO Feb 23 '24 Sale 400.32 100,000 40,032,000 5,289,947 Feb 27 04:17 PM Troendle August J. CEO Feb 26 '24 Sale 402.38 56,928 22,906,689 5,233,019 Feb 27 04:17 PM Medpace Investors, LLC 10% Owner Feb 23 '24 Sale 400.32 100,000 40,032,000 5,289,947 Feb 27 04:09 PM Medpace Investors, LLC 10% Owner Feb 26 '24 Sale 402.38 56,928 22,906,689 5,233,019 Feb 27 04:09 PM Medpace Investors, LLC 10% Owner Feb 22 '24 Sale 395.98 100,000 39,598,000 5,389,947 Feb 23 04:15 PM Medpace Investors, LLC 10% Owner Feb 21 '24 Sale 383.44 36,012 13,808,441 5,489,947 Feb 23 04:15 PM Troendle August J. CEO Feb 22 '24 Sale 395.98 100,000 39,598,000 5,389,947 Feb 23 04:11 PM Troendle August J. CEO Feb 21 '24 Sale 383.44 36,012 13,808,441 5,489,947 Feb 23 04:11 PM Carley Brian T Director Feb 20 '24 Option Exercise 26.44 13,782 364,396 21,595 Feb 22 04:06 PM Medpace Investors, LLC 10% Owner Feb 16 '24 Sale 391.75 50,000 19,587,500 5,539,947 Feb 21 04:50 PM Medpace Investors, LLC 10% Owner Feb 20 '24 Sale 386.39 13,988 5,404,823 5,525,959 Feb 21 04:50 PM Troendle August J. CEO Feb 16 '24 Sale 391.75 50,000 19,587,500 5,539,947 Feb 21 04:45 PM Troendle August J. CEO Feb 20 '24 Sale 386.39 13,988 5,404,823 5,525,959 Feb 21 04:45 PM McCarthy Cornelius P. III Director Feb 08 '24 Option Exercise 57.17 4,710 269,271 5,038 Feb 12 04:06 PM BURWIG SUSAN E Exec. VP, Operations Dec 14 '23 Sale 304.15 10,391 3,160,423 17,292 Dec 18 05:03 PM BURWIG SUSAN E Exec. VP, Operations Dec 15 '23 Sale 303.00 2,009 608,727 15,283 Dec 18 05:03 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite